Literature DB >> 7475546

Gaucher's disease variant characterised by progressive calcification of heart valves and unique genotype.

A Abrahamov1, D Elstein, V Gross-Tsur, B Farber, Y Glaser, I Hadas-Halpern, S Ronen, M Tafakjdi, M Horowitz, A Zimran.   

Abstract

Gaucher's disease is the most prevalent sphingolipid storage disease, characterised by substantial genetic and phenotypic variability. Cardiac manifestations are rare. We report 12 Arab Gaucher's disease patients, 2-20 years of age, who presented with oculomotor apraxia but only slight classic signs of the disease. All but the youngest had calcifications of the aortic or mitral valves or both. All these patients were homozygous for the rare point mutation D409H (1342C). Valvular calcifications increased with age and showed progression during 2 years of follow-up. Two of the oldest patients underwent aortic valve replacement, and one sibling had died suddenly at age 16, before this study, Corneal opacities were another common feature. The potentially fatal course of this Gaucher's disease variant, and the availability of a reliable PCR-based method for heterozygote detection, mean that population screening and genetic counselling in the geographic area at risk are important. Affected individuals should be closely monitored by echocardiography to gauge the need for valve replacement. The potential of enzyme replacement to prevent these cardiac complications cannot be ascertained at present, because of the high cost of therapy.

Entities:  

Mesh:

Year:  1995        PMID: 7475546     DOI: 10.1016/s0140-6736(95)91688-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  44 in total

Review 1.  Management of neuronopathic Gaucher disease: a European consensus.

Authors:  A Vellodi; B Bembi; T B de Villemeur; T Collin-Histed; A Erikson; E Mengel; A Rolfs; A Tylki-Szymanska
Journal:  J Inherit Metab Dis       Date:  2001-06       Impact factor: 4.982

2.  Mutation analysis in 46 British and Irish patients with Gaucher's disease.

Authors:  C E Hatton; A Cooper; C Whitehouse; J E Wraith
Journal:  Arch Dis Child       Date:  1997-07       Impact factor: 3.791

3.  Gaucher's Disease with Cardiac Valve Calcification and Stenosis: A Rare Presentation due to Homozygous p.D409H Mutation in a North Indian Family.

Authors:  Pulkit Rastogi; Sandeep Rao; Jasbir Kaur; Pankaj Malhotra; Subhash Varma; Reena Das
Journal:  Indian J Pediatr       Date:  2016-02-18       Impact factor: 1.967

4.  Progression of retinal changes in Gaucher disease: a case report.

Authors:  R G Coussa; J C P Roos; M Aroichane; M-C Miron; L H Ospina
Journal:  Eye (Lond)       Date:  2013-08-23       Impact factor: 3.775

5.  Gaucher disease plus.

Authors:  E Sidransky; E I Ginns
Journal:  J Med Genet       Date:  1997-10       Impact factor: 6.318

6.  D409H/D409H genotype in Gaucher-like disease.

Authors:  E Uyama; M Uchino; H Ida; Y Eto; M Owada
Journal:  J Med Genet       Date:  1997-02       Impact factor: 6.318

7.  Neonatal cholestasis as initial manifestation of type 2 Gaucher disease: a continuum in the spectrum of early onset Gaucher disease.

Authors:  Abdallah F Elias; Maria Ronningen Johnson; John K Boitnott; David Valle
Journal:  JIMD Rep       Date:  2011-12-11

8.  Successful screening for Gaucher disease in a high-prevalence population in tabuleiro do Norte (northeastern Brazil): a cross-sectional study.

Authors:  Rigoberto Gadelha Chaves; Janice Carneiro Coelho; Kristiane Michelin-Tirelli; Tibelle Freitas Maurício; Edineide de Freitas Maia Chaves; Paulo César de Almeida; Carlos Rômulo Filgueira Maurício; Geraldo Barroso Cavalcanti
Journal:  JIMD Rep       Date:  2011-06-22

Review 9.  A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease.

Authors:  E H Davies; R Surtees; C DeVile; I Schoon; A Vellodi
Journal:  J Inherit Metab Dis       Date:  2007-09-16       Impact factor: 4.982

10.  Clinical and molecular characteristics of Japanese Gaucher disease.

Authors:  Y Eto; H Ida
Journal:  Neurochem Res       Date:  1999-02       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.